Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

The best out-of-the-box tricks to treat atopic dermatitis (eczema), according to expert dermatologists, plus products to try.

Jason B. Pieper, DVM, MS, DACVD, talks about the multiple therapies available for cases of moderate and severe atopic dermatitis and delves into each option ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Treating eczema starts with a solid skincare routine, but you may need more than just moisturizer to get you through a flare-up.